ストックスクリーナーアプリを入手
23.37
2.82%
0.64
前日終値:
$22.73
開ける：
$21.96
24時間の取引高:
1.41M
Relative Volume:
0.48
時価総額：
$2.97B
収益：
$24.05M
当期純損益:
$-243.33M
株価収益率:
-7.789
EPS:
-3.0004
ネットキャッシュフロー:
$-370.18M
1週間 パフォーマンス:
-11.21%
1か月 パフォーマンス:
-21.37%
6か月 パフォーマンス:
+490.15%
1年 パフォーマンス:
+137.50%
1日の値動き範囲:
$21.62
$23.89
1週間の範囲:
$19.86
$26.25
52週間の値動き範囲:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Compare ALMS vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
23.37 | 2.97B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | 開始されました | Raymond James | Strong Buy |
| 2026-02-25 | 開始されました | Stifel | Buy |
| 2026-01-21 | 開始されました | Chardan Capital Markets | Buy |
| 2025-07-25 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | 再開されました | Guggenheim | Buy |
| 2025-01-30 | 開始されました | Oppenheimer | Outperform |
| 2024-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 開始されました | Guggenheim | Buy |
| 2024-07-23 | 開始されました | Leerink Partners | Outperform |
| 2024-07-23 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Alumis Inc (ALMS) 最新ニュース
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - sahmcapital.com
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why Alumis Inc. Shares Are Suddenly Surging - tipranks.com
HC Wainwright Brokers Raise Earnings Estimates for Alumis - MarketBeat
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - biospace.com
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - marketbeat.com
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - GuruFocus
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News - GuruFocus
Why is Alumis stock falling Monday? - MSN
Alumis price target raised to $55 from $50 at Oppenheimer - tipranks.com
Why Is Alumis Stock Falling Monday?Alumis (NASDAQ:ALMS) - Benzinga
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade - MarketBeat
Leerink reiterates Alumis stock rating on consistent trial data - Investing.com UK
US Stocks Recap: Is Alumis Incs growth already priced inTrade Exit Report & Verified Short-Term Plans - baoquankhu1.vn
Leerink reiterates Alumis stock rating on consistent trial data By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Alumis stock after trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Alumis stock after trial data - Investing.com India
Alumis (NASDAQ:ALMS) Given New $55.00 Price Target at Oppenheimer - MarketBeat
Guggenheim reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Baird reiterates Alumis stock rating on Phase 3 data strength - Investing.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data - Investing.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Envudeucitinib Shows Early, Robust Skin Clearance and Quality of Life Improvements in Phase 3 Plaque Psoriasis Trials by Alumis Inc. 123 - minichart.com.sg
Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating - MarketScreener
Alumis stock price target lowered to $25 by H.C. Wainwright on competitive pressures - Investing.com India
Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com - Investing.com Canada
Chardan Capital Reiterates "Buy" Rating for Alumis (NASDAQ:ALMS) - MarketBeat
Stifel reiterates Alumis stock Buy rating after psoriasis data - Investing.com
HC Wainwright Cuts Alumis (NASDAQ:ALMS) Price Target to $25.00 - MarketBeat
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib - tipranks.com
Alumis Inc. Soars On Breakthrough Psoriasis Drug Update - tipranks.com
Alumis: Envudeucitinib Shows Robust PASI 90/100 Responses and QoL Gains in Phase 3 ONWARD Trials - TradingView
Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA - Stock Titan
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout - MarketBeat
Alumis (ALMS) Confronts Potential Regulatory Reassessment with NDA Submission Expected in Second Half of 2026 - Bitget
A Look At Alumis (ALMS) Valuation After ONWARD Phase 3 Psoriasis Data And FDA Filing Plans - simplywall.st
Alumis reports Phase 3 psoriasis trial results for envudeucitinib By Investing.com - Investing.com South Africa
Alumis’ Envudeucitinib Meets Co-Primary Endpoints in ONWARD1 and ONWARD2 Phase 3 Trials - Dermatology Times
Alumis reports Phase 3 psoriasis trial results for envudeucitinib - Investing.com
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - manilatimes.net
Alumis Inc (ALMS) 財務データ
収益
当期純利益
現金流量
EPS
Alumis Inc (ALMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):